As the IPO market gradually recovers in 2025, global investors have turned their attention to 2026, a year that could define the next decade. Among the many emerging tech giants rumored to be going public, two names consistently dominate the headlines: SpaceX, the space exploration company founded by Elon Musk, and OpenAI, the AI revolution spearheaded by Sam Altman. They are not only symbols of cutting-edge technology but also have the potential to become the largest IPOs in history. If both companies do go public in the same year, how should investors choose? 🚀 SpaceX: Packing the Interstellar Future into its Prospectus Founded in 2002 by serial entrepreneur Elon Musk, SpaceX aims to reduce launch costs through reusable rocket technology, with the ultimate goal of achieving travel to the

As the legendary era of the "Oracle of Omaha," Warren Buffett, draws to a close, his successor, Greg Abel, has officially been CEO of Berkshire Hathaway $Berkshire Hathaway(BRK.A)$ for just a month. Yet, a major move seems to be quietly brewing—one that could signal a rewrite of the company's long-standing investment philosophy. Recently, a regulatory filing stirred the market like a stone thrown into a calm lake: Berkshire may be preparing to sell its entire stake in Kraft Heinz $The Kraft Heinz Company(KHC)$ . Could this be the first defining moment of the "Post-Buffett Era"? ⚠️ An Unusual Risk Warning On Tuesday, food giant $The Kraft Heinz Company(KHC)$ incl

Since the start of 2025, the silver market has staged a spectacular rally. By the end of December 2025, silver prices had accumulated a staggering gain of approximately 171%. During the session on December 26, prices briefly touched a high of $80 per ounce before closing the year at around $72. Entering 2026, $iShares Silver Trust(SLV)$ continues to lead the commodities pack, emerging as the brightest performing asset in the Bloomberg Commodity Index. Meanwhile, the Gold-Silver Ratio—which measures how many ounces of silver it takes to buy one ounce of gold—has rapidly slid from recent highs to around 57. This is not only far below the long-term average of 68 but also marks a new low since 2013, signaling a strong "catch-up" momentum for silver rel

As spot gold prices forcefully break through$4,600 per ounce and continue to climb, multiple major institutions have set their sights on a target of $5,000 within the year. Driven by a combination of geopolitical risks, shifts in global monetary policy, and sustained central bank buying, the upward momentum for gold has been significantly reinforced.For investors looking to capitalize on this trend, buying physical gold isn't the only option. A selection of gold mining companies—characterized by solid fundamentals, production growth, and financial stability—offers a tool with greater leverage to play this rally.The following industry-leading companies are well-positioned to benefit directly from rising gold prices, each representing different regions, business models, and growth paths:1. <

Although high-valuation stocks in the current U.S. stock market continue to rise, and value stocks have lagged far behind growth stocks in recent years, stock valuations are still crucial for investors. Specifically in the medical sector, although the performance of U.S. medical stocks in the past two years has not been outstanding, the valuation is also lower than the $.SPX(.SPX)$ index. As market expectations for the medical sector improve, the industry will also regain the favor of value investors.Looking ahead to the next five years, the following two U.S. medical value stocks are expected to shine.U.S. medical value stocks 1: $Moderna, Inc.(MRNA)$ Moderna has become a household name for developing an

It’s no secret that big pharmaceutical companies like $Eli Lilly(LLY)$ need to get regulators to agree that their drugs are safe and effective before they can make money. But regulators aren’t the only group companies need to appease before shareholders see returns.On October 23, Eli Lilly’s Alzheimer’s drug Kisunla was approved in the UK by the Medicines and Healthcare Products Regulatory Agency (MHRA), following in the footsteps of the US Food and Drug Administration (FDA) and Japanese regulators. UK regulators agreed with clinical trial results that showed the drug was somewhat effective in slowing or stopping the rate of cognitive decline associated with the disease for up to about seven months. They also found that treatment-related side effects,

In August 2011, just a few years after the financial crisis, Standard & Poor’s downgraded the U.S. credit rating from AAA (the highest rating) to AA+ (the second highest). Then, in August 2023, Fitch followed suit, lowering the U.S. from AAA to AA+. Both S&P and Fitch still see the U.S. as having an extremely low risk of default, but that top-tier status is undeniably gone.Many U.S. companies have faced a similar fate. Back in 1980, around 60 publicly traded companies held AAA credit ratings. After more than four decades of acquisitions, mergers, bankruptcies, innovation, and economic shifts, only two companies still hold this perfect rating: tech giant $Microsoft(MSFT)$ and healthcare powerhouse $John

In the stock market, you don’t need to bet everything on expensive stocks to invest in quality companies. There are still solid options available at reasonable prices, like $Exelixis(EXEL)$ , which is currently trading below $40.Major Wins for ExelixisExelixis is a biotechnology company focused on oncology, with its most important product being Cabometyx, used to treat renal cell carcinoma (a type of kidney cancer) and hepatocellular carcinoma (liver cancer).Cabometyx has been the cornerstone of Exelixis’s revenue for some time. In Q2, its revenue grew 35.6% year-over-year, reaching $637.2 million. Cabometyx alone accounted for $437.6 million in the U.S., making up nearly 69% of the company's total revenue.While relying heavily on one product carr

Ryan_Z0528: +175% on $OKLO in 22 Days , The electricity value train：https://x.com/EricFlaningam/status/1848009956961685536 Investors are flocking to power-related stocks, and California-based advanced nuclear systems developer $Oklo Inc.(OKLO)$ has seen its stock price double, skyrocketing by 115% to a record high of $19.72, peaking at $20.64 and giving it a market cap of over $2.4 billion.Oklo went public in May through a merger with the special purpose acquisition company (SPAC) AltC Acquisition, experiencing volatile stock movements since then. The nuclear stock had fallen to a low of $5.35 on September 9 but has jumped over 200% in the past six weeks.Oklo is working on developing small modular reactors (SMRs) and plans to deliver its first rea

The GLP-1 weight-loss drug market is massive, but the competition is fierce. Instead of joining the race, Swiss pharma giant $Novartis AG(NVS)$ is playing it smart, focusing on more strategic growth areas.Novartis is sticking to what it’s good atCEO Vas Narasimhan recently said in an interview that the company has no plans to jump into the "crazy" weight-loss market, claiming they’ve got better options. He’s aiming to invest in projects with bigger potential payoffs, like radioligand cancer therapies, which could bring in up to $20 billion.Novartis is also eyeing other opportunities in treatments for Parkinson's, Huntington's, and Alzheimer’s diseases. Compared to the ultra-competitive weight-loss field, these areas might offer more solid ground fo

$Eli Lilly(LLY)$ is now one of the most valuable healthcare companies globally, boasting a market cap of over $800 billion. With its stock price surging more than 50% in the past 12 months, some investors may feel hesitant due to its price-to-earnings (P/E) ratio exceeding 100 times. However, there are strong reasons to consider Eli Lilly despite the high valuation. Here are three factors that suggest its valuation could continue to climb in the coming months and years:1. Tirzepatide's Undervalued PotentialEli Lilly has seen major success with FDA approvals, notably for the weight-loss drug Zepbound and the diabetes drug Mounjaro, both containing the same active ingredient: tirzepatide. These drugs are in the early stages of their growth cycles, an

Historically, small-cap stocks have thrived once the Fed begins cutting rates. Globally, markets in Japan, China, and the UK currently offer attractive valuations, providing interesting opportunities for investors.Small and Mid-Cap Stocks: Poised for GainsAccording to Brian G. Belski, chief investment strategist at BMO Capital Markets, valuations for small-cap and mid-cap stocks are appealing for investors looking to increase exposure. Data shows that small-cap stocks (S&P SmallCap 600) are still trading below their 20-year average, while mid-cap stocks (S&P MidCap 400) are only slightly above it. In contrast, the $.SPX(.SPX)$ is trading well above its 20-year average.Since 1995, in the year following the Fed’s first rate cut, the S&P

As the $.SPX(.SPX)$ approaches its all-time high, some undervalued components like $Pfizer(PFE)$ $AbbVie(ABBV)$ are flying under the radar. Both of these healthcare stocks boast dividend yields over 3% and are poised for further increases, making them likely candidates to outperform the S&P 500 in the next decade.1. $Pfizer(PFE)$Last December, Pfizer raised its dividend for the 15th consecutive year, with a current yield of 5.8%. Even without additional hikes, this stock can provide substantial passive income. With many new patented drugs in the pipeline, investors can reasonably expect steady quarterly dividend increa